See the DrugPatentWatch profile for Ustekinumab
Ustekinumab, marketed as Stelara, is a biologic medication used to treat conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The patent landscape for ustekinumab is complex, with multiple patents covering different aspects of the drug, including its composition, manufacturing processes, and methods of use.
When is ustekinumab patent expiry expected?
The primary patents for ustekinumab are expected to expire around late 2023 in the United States, paving the way for potential biosimilar entry [1]. However, the exact timing of patent expiry can be influenced by various legal challenges and patent term extensions.
What are the key patents covering ustekinumab?
Several patents are associated with ustekinumab. These include patents related to the antibody itself, its formulation, and specific indications for its use. For instance, patents covering the treatment of plaque psoriasis and psoriatic arthritis are particularly relevant to its market exclusivity [2].
What is the potential impact of patent expiry on ustekinumab availability?
Once key patents expire, it opens the door for the development and approval of ustekinumab biosimilars. Biosimilars are highly similar to reference biologics and are expected to offer more affordable treatment options for patients [3].
What is the regulatory pathway for ustekinumab biosimilars?
In the United States, biosimilars are regulated by the Food and Drug Administration (FDA) under the Biologics Price Competition and Innovation Act (BPCIA). Companies seeking to market a biosimilar must demonstrate that their product is highly similar to the reference product and has no clinically meaningful differences in terms of safety, purity, and potency [3].
How does ustekinumab compare to other treatments for inflammatory conditions?
Ustekinumab is a biologic that targets the interleukin-12 (IL-12) and interleukin-23 (IL-23) pathways. It is prescribed for patients with moderate to severe inflammatory diseases who have not responded adequately to other therapies or cannot tolerate them. Other treatment options for these conditions include other biologic agents targeting different pathways (e.g., TNF-alpha inhibitors, IL-17 inhibitors), as well as conventional immunosuppressants and small molecule drugs [4].
Who are the main competitors for ustekinumab?
The competitive landscape for ustekinumab includes other biologic therapies approved for similar indications. These include drugs like adalimumab (Humira), secukinumab (Cosentyx), and ixekizumab (Taltz), which target different inflammatory pathways and are also facing or will face patent expirations, leading to biosimilar and interchangeable biosimilar competition [5].
What are the legal challenges affecting ustekinumab patents?
Patent litigation is common for high-value biologic drugs. Challenges to ustekinumab patents may involve arguments about patent validity, infringement, and inventorship. Such legal battles can significantly influence the timeline for biosimilar market entry [1]. Information on specific patent disputes and their outcomes can often be found on specialized resources like DrugPatentWatch.com [6].
What is the global patent status for ustekinumab?
Patent expiry timelines can vary by country. While U.S. patents are a major focus, expiry dates for corresponding patents in other major markets, such as Europe and Japan, will also impact global biosimilar competition [2].
What are the financial implications of ustekinumab patent expiry?
The expiry of patents for blockbuster drugs like ustekinumab typically leads to significant price reductions due to the introduction of biosimilars. This can result in substantial savings for healthcare systems and patients, while also impacting the revenue of the originator company [3].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com
4. DrugPatentWatch.com
5. DrugPatentWatch.com
6. DrugPatentWatch.com